%0 Journal Article
%T Hepatitis A virus vaccination in childhood
%A A Adrovic
%A B S Kocazeybek
%A K Barut
%A O F Beser
%A O Kasapcopur
%A P Yuksel
%A S Mertoglu
%A S Sahin
%A S Sazak
%J Lupus
%@ 1477-0962
%D 2019
%R 10.1177/0961203318819827
%X Objectives: Vaccination of systemic lupus erythematosus patients with non-live vaccines may decrease vaccine-preventable infections and mortalities. In the present study, we aimed to compare the immunogenicity and safety of inactivated hepatitis A vaccination in childhood-onset systemic lupus erythematosus and healthy subjects. Methods: A total of 30 childhood-onset systemic lupus erythematosus and 39 healthy participants who were seronegative for hepatitis A received two doses of the hepatitis A vaccine in a 0- and 6-month schedule. Hepatitis A virus (HAV) IgG antibodies were measured before vaccination and 7 months after the vaccination. Results: Although anti-HAV IgG antibody titers after vaccination were found to be somewhat lower in children with systemic lupus erythematosus than that of the healthy subjects (p£¿<£¿0.05), the difference in seroconversion rate was insignificant between childhood-onset systemic lupus erythematosus patients (n£¿=£¿24/30, 80%) and healthy controls (n£¿=£¿33/39, 84.6%). There was no increase in median Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K scores and anti-ds DNA levels after the vaccination procedure. Seroconversion rates in childhood-onset systemic lupus erythematosus patients were not affected by medication, high disease activity (SLEDAI-2K >6) and anti-ds DNA positivity. None of the patients experienced any flare or adverse reaction throughout the study. Conclusions: According to these results, we conclude that inactivated hepatitis A vaccine is safe and well tolerated in childhood-onset systemic lupus erythematosus patients, with no adverse events or increase in activity. Immunogenicity to the hepatitis A vaccine was adequate, with a seropositivity rate of 80%
%K Anti-HAV
%K childhood-onset systemic lupus erythematosus
%K efficacy
%K hepatitis A virus vaccination
%K safety
%U https://journals.sagepub.com/doi/full/10.1177/0961203318819827